The T-Cell therapy developer has received funding in a Gilead Sciences-backed series B round led by Fidelity Management and Research.

UnityPoint Health has launched a corporate venturing arm, UnityPoint Health Ventures Innovation Fund, that will invest in areas such as digital health and medical devices.

GlaxoSmithKline, Novartis and Astellas are among the investors to have celebrated an exit after cancer therapy developer Bicycle secured $60.7m in its initial public offering.

UCB Ventures and Alphabet unit GV took part in the RNA-targeting gene therapy developer's first publicly disclosed funding round, which was led by Arch Venture Partners.

GuideWell Mutual, Blue Shield California and existing backer Premera Blue Cross all invested in the healthcare prediction platform developer.

Cambridge Innovation Capital has celebrated an exit as Bicycle Therapeutics successfully lists in the US.

University of Calgary-born Parvus Therapeutics has inked an $800m deal with Genentech to develop and commercialise treatments for autoimmune diseases.

Merck & Co and Lilly Asia Ventures will exit the biotherapeutics technology developer in an acquisition by Evotec that will be sized at up to $90m.

Eli Lilly, WuXi Biologics and Alexandria-backed cancer and orphan disease therapy developer Inhibrx has received $40m in funding from Viking Global Investors.

MassMutual Ventures co-led the healthcare data platform developer's series B round, which also featured Aviva Ventures and Jianke.